Intellia Therapeutics NTLA Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $66.09M-2.3% | $67.67M+17.6% | $57.53M+8.8% | $52.86M+16.0% | $45.57M-21.3% | ||
| $361.17M-7.1% | $388.86M-6.8% | $417.09M-6.4% | $445.72M-3.7% | $462.89M-0.7% | ||
| $125.64M+4.9% | $119.8M+0.5% | $119.17M0.0% | $119.16M-3.7% | $123.75M-1.7% | ||
| $486.81M-4.3% | $508.66M-5.1% | $536.26M-5.1% | $564.88M-3.7% | $586.64M-0.9% | ||
| -$420.72M+4.6% | -$440.99M+7.9% | -$478.73M+6.5% | -$512.02M+5.4% | -$541.07M-1.3% | ||
| -636.6%+15.1pp | -651.7%+180pp | -832.2%+137pp | -968.7%+219pp | -1,187.4%-264pp | ||
| $25.8M-11.6% | $29.2M-12.5% | $33.35M-14.0% | $38.76M-11.5% | $43.78M-8.4% | ||
| $26.12M-7.7% | $28.3M-14.0% | $32.92M+3.4% | $31.83M+110% | $15.15M-0.6% | ||
| $1.22M— | $0+100% | -$429K+93.8% | -$6.93M+75.8% | -$28.63M+12.1% | ||
| -$394.6M+4.4% | -$412.69M+7.4% | -$445.81M+7.2% | -$480.19M+8.7% | -$525.91M-1.3% | ||
| -597%+12.8pp | -609.9%+165pp | -774.9%+134pp | -908.5%+246pp | -1,154.1%-257pp | ||
| -$3.53+7.6% | -$3.82+10.3% | -$4.26+9.0% | -$4.68+10.3% | -$5.22+0.4% | ||
| -$3.53+7.6% | -$3.82+10.3% | -$4.26+9.0% | -$4.68+10.3% | -$5.22+0.4% | ||
| 440.8M+3.5% | 425.8M+2.3% | 416.3M+2.3% | 407.1M+1.7% | 400.3M+2.0% | ||
| 440.8M+3.5% | 425.8M+2.3% | 416.3M+2.3% | 407.1M+1.7% | 400.3M+2.0% | ||
| -$395.89M+4.0% | -$412.27M+8.0% | -$448.11M+6.3% | -$478.39M+8.7% | -$523.91M-1.1% | ||
| —— | $0— | $0— | $0— | $0— | ||
| $26.12M-7.7% | $28.3M-14.0% | $32.92M+3.4% | $31.83M+110% | $15.15M-0.6% | ||
| $66.09M-2.3% | $67.67M+17.6% | $57.53M+8.8% | $52.86M+16.0% | $45.57M-21.3% | ||
| -$420.72M+4.6% | -$440.99M+7.9% | -$478.73M+6.5% | -$512.02M+5.4% | -$541.07M-1.3% | ||
| -$411.23M+4.6% | -$431.21M+8.0% | -$468.76M+6.6% | -$501.86M+5.5% | -$530.8M-1.3% | ||
| -$411.23M+4.6% | -$431.21M+8.0% | -$468.76M+6.6% | -$501.86M+5.5% | -$530.8M-1.3% | ||
| -622.2%+15.0pp | -637.2%+178pp | -814.8%+135pp | -949.5%+215pp | -1,164.8%-259pp | ||
| -$420.72M+4.6% | -$440.99M+7.9% | -$478.73M+6.5% | -$512.02M+5.4% | -$541.07M-1.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Intellia Therapeutics's revenue?
- Intellia Therapeutics (NTLA) generated $66.1M in revenue over the trailing twelve months, up 45.0% year over year.
- Is Intellia Therapeutics profitable?
- Intellia Therapeutics is not currently profitable: it reported a net loss of $394.6M over the trailing twelve months, a -597.0% net margin.
- What is Intellia Therapeutics's earnings per share?
- Intellia Therapeutics's diluted EPS over the trailing twelve months is $-3.53.
- Where does Intellia Therapeutics's income statement data come from?
- Every line is extracted from Intellia Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
